Foxconn: The world's largest contract electronics maker has already been diversifying its supply chain, expanding production ...

The German pharma and ... predicted 2024 sales between 20.7 billion and 22.1 billion euros, said it was now guiding for the ...

The German pharmaceutical company is expected to post ... Thye raises Hartalega’s FY 2025 earnings forecast by 13% to factor in higher sales volume. Public IB raises Hartalega’s target price to ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day everyone and welcome to today’s Avadel Pharmaceuticals ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

The country contributed $5.05 billion in sales in the first nine months of 2024, or 13% of the British pharma’s total haul of ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...